GB2034030A - Analytical Test Article and Method - Google Patents
Analytical Test Article and Method Download PDFInfo
- Publication number
- GB2034030A GB2034030A GB7842687A GB7842687A GB2034030A GB 2034030 A GB2034030 A GB 2034030A GB 7842687 A GB7842687 A GB 7842687A GB 7842687 A GB7842687 A GB 7842687A GB 2034030 A GB2034030 A GB 2034030A
- Authority
- GB
- United Kingdom
- Prior art keywords
- labelled
- substance
- sample
- diagnostic reagent
- surface region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 65
- 238000004458 analytical method Methods 0.000 title description 3
- 239000000126 substance Substances 0.000 claims abstract description 104
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 57
- 238000001514 detection method Methods 0.000 claims abstract description 24
- 238000005406 washing Methods 0.000 claims abstract description 16
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 claims abstract description 15
- 230000027455 binding Effects 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 238000005259 measurement Methods 0.000 claims description 8
- 239000007795 chemical reaction product Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 4
- 239000006185 dispersion Substances 0.000 claims description 3
- 239000000427 antigen Substances 0.000 abstract description 33
- 102000036639 antigens Human genes 0.000 abstract description 32
- 108091007433 antigens Proteins 0.000 abstract description 32
- 238000012360 testing method Methods 0.000 abstract description 12
- 238000003127 radioimmunoassay Methods 0.000 abstract description 7
- 238000000926 separation method Methods 0.000 abstract description 4
- 230000009137 competitive binding Effects 0.000 abstract description 2
- 238000002798 spectrophotometry method Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 18
- 239000007787 solid Substances 0.000 description 17
- 239000000758 substrate Substances 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 12
- 241000283707 Capra Species 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 239000007822 coupling agent Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- -1 antibodies Substances 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 208000006379 syphilis Diseases 0.000 description 3
- BBEQQKBWUHCIOU-UHFFFAOYSA-N 5-(dimethylamino)-1-naphthalenesulfonic acid(dansyl acid) Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(O)(=O)=O BBEQQKBWUHCIOU-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 201000005702 Pertussis Diseases 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- 238000005558 fluorometry Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- XJENLUNLXRJLEZ-UHFFFAOYSA-M lissamine rhodamine Chemical compound [Na+].C=12C=C(C)C(N(CC)CC)=CC2=[O+]C=2C=C(N(CC)CC)C(C)=CC=2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O XJENLUNLXRJLEZ-UHFFFAOYSA-M 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 108010075210 streptolysin O Proteins 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 241001640117 Callaeum Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- KKCIOUWDFWQUBT-AWEZNQCLSA-N L-thyronine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1OC1=CC=C(O)C=C1 KKCIOUWDFWQUBT-AWEZNQCLSA-N 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 241001290864 Schoenoplectus Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 108010011834 Streptolysins Proteins 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000007420 radioactive assay Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000012487 rinsing solution Substances 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
- G01N33/521—Single-layer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
A body and method for the quantitative detection of an unknown quantity of a biologically derived sample, suitably by radioimmunoassay, fluorometric detection, or by spectrophotometry. The body of the invention includes a handle attached to a nonparticulate, nonswellable, impermeable continuous surface region (although the presence of a handle is not essential in the method). A diagnostic reagent (e.g., an antibody) is covalently attached to the surface region. In a competitive binding technique, the sample under test and a labelled substance (e.g., fluorochrome labelled antigen) are simultaneously contacted with the body. Thereafter, the surface region is washed, and the label is measured (e.g. by a fluorometer). Using the so- called "sandwich technique" the labelled substance (e.g., labelled antibody) is reacted with the sample substance after it has been reacted with the diagnostic reagent. The above type of surface facilitates simple and effective separation of bound from free labelled substance and allows thorough washing to cleanse the surface of residual free and non-specifically bound labelled substance.
Description
SPECIFICATION
Analytical Test Article and Method
This invention relates to a body suitable for use in (e.g. fluorometric) detection of a biologically derived sample and to a method of such detection.
There are a multitude of techniques employed for the quantitative determination of an unknown quantity of a sample derived from a biological fluid (e.g., serum or urine). Techniques based upon radioactive labelled substances include indirect (competitive binding, saturation or displacement) and direct (sandwich and immunoradiometric) radioimmunoassays. Other known techniques are based on fluorochrome and enzyme labels. After completion of the above reactions, the labelled substances which have been bound must be separated from the unreacted labelled substance which includes free and non-specifically bound substance. This separation step in liquid form can be inefficient, unreliable and inconvenient.
A number of techniques have been proposed to solve this problem by use of diagnostic reagents on solid surfaces which combine with the labelled substance. In each of these systems, the solid substrate containing the bound labelled substance is separated from the liquid phase containing the free labelled substance and is thereafter washed to remove the residual free and the non-specifically bound labelled substance.
In one technique for the detection of antigen, reagents are coated upon plastic test tubes or inserts by the physical adsorption of antibodies specific to the sample substances to be tested.
Such techniques are disclosed in U.S. Patents 3,646,346 and 3,826,619. Such physical adsorption is difficult to control because of the non-uniformity of plastic surfaces as well as imprecision in the coating techniques. See, e.g., the work entitled "Radioimmunoassay Methods",
European Workshop, September 1 5-17, 1970, Edinburgh (Editors Kirkham et al). At page 441, the authors state that the amount of binding is between 20% and 70% using various coated polystyrene tubes in a particular system, which led to the abandonment of this technique.
Furthermore, in subsequent immunochemical reactions, a significant amount of "non-specific" binding of the labelled substance to the solid surface occurs. This binding, of a hydrophobic or ionic nature, is weaker than the immunochemical bond. Hence, vigorous and repeated washings required to effectively remove solution residual and non-specifically bound labelled substance frequently disrupt the weaker physical coated bond resulting in the loss of physically bound diagnostic reagent This results of assays employing such coated surfaces are thus relatively imprecise and non-reproducible because of these kinds of misclassification errors.
(Envoll et al, Biochim. Biophys. Acta, 251 (1971) 427-434, at p. 450). Another disadvantage of physically coating as with antibodies is that the
antibodies in that form are relatively unreactive with large antigens. It is believed that this is due to steric hindrance effects.
In the technique of Bennich et al U.S. Patent 3,720,760, immunological substances are more firmly secured by attachment to porous
microreticular swellable polymer of the type sold
under the trademark "Sephadex". Such material is indicated as being preferably in particulate form. Such microreticular materials have the inherent disadvantage of being difficult to wash their interstitial void spaces free of nonspecifically bound and entrained free labelled substance. This results in undesirably high background readings. Also, it is difficult to rinse the interparticulate void spaces sufficiently free of residual free labelled substances, generally requiring several displacement washes. Each washing step requires a centrifugal and careful decantation separation to avoid misclassification to minimize inadvertant spillage of particles during the washing procedure.
This technique is unsuitable in fluorometric and colorimetric surface systems because the particles cannot be accurately viewed. This is because loose microreticular beads used in radioactive assays produce an ill-defined and difficult to control surface for uniform illumination and viewing.
Another technique which has been proposed is described in an article entitled "Solid Phase Disc
Radioimmunoassay of Human Growth Hormone" by Catt et al, J. Lab. & Clin. Med., (1966)100, 31 c. Small discs of substituted graft copolymer sold under the trademark "Protapol Gel/1 ", are coated with antibody. As set forth in the above
Kirkham et al work, at pages 294 and 295, this technique yields poor replication, i.e., there is a very wide scatter between the replicates at any given point, and sometimes the differences are very large. The discs require repeated handling and each time they are touched by a solid object the chance for loss of bound labelled substance or contamination by free labelled substance or other background contributing contaminants is considerable.Like the above particle technique, the disc would not be accurately viewed in fluorometric or colorimetric systems and would be difficult to manipulate into proper viewing relationship with an optical instrument.
In view of the foregoing, there is an apparent need for a solid phase analytical technique in which the surface is easy to wash, separations are easy to make, which is efficient and reproducible, and which can be presented easily for accurate viewing.
In accordance with the present invention, a body is provided which is suitable for use in the labelled quantitative determination of a biologically derived sample. The body includes a handle attached to at least one nonparticulate, nonswellable, impermeable continuous surface region covalently attached to a diagnostic reagent which is reactive with the biologically derived sample. The surface with the attached reagent (e.g., antibody) is reacted with the sample substance (e.g., antigen). In one competitive technique, the labelled substance (e;g., fluorochrome-labelled antigen) is simultaneously reacted with the sample substance. In a sandwich technique, the labelled substance (e.g., fluorochrome-labelled antibody) is subsequently reacted.In another type of competitive technique, the attached reagent and sample substance are the same, and they both are simultaneously reacted with labelled substance, (e.g., fluorochrome labelled antibody). In any of these techniques, the reaction of the surface and sample is accelerated by stirring with the handle.
Then, the surface is conveniently separated from the sample and transported by the-handle-of the body to a detection station for measuring the amount of labelled substance without need to touch the-surface.
In one embodiment, the body includes at least two attached diagnostic reagent regions in which one contains a standard region of a predetermined-quantity of the labelled substance.
In other embodiment, the body is polyhedral and has a different diagnostic reagent on each of a plurality of its faces. Also, a plurality of diagnostic reagents may be attached in a single region in random dispersion and reacted with at least two different sample substances and labelled substances which emit different signals.
A body of the foregoing type having a handle facilitates, of course, non-touchable handling of the solid surface and eliminates the need to centrifuge and decant. Furthermore, the body and method of the invention can be employed for reproducible precise sample detection with low background noise and minimal mis-classification error.
The invention will now be further illustrated and described with reference to the accompanying drawings, in which:
Figure 1 is å schematic-view of one embodiment of the body of the invention (handle not shown) viewed by a fluorometric system; and
Figures 2 and 3 are-different embodiments of the body of the system.
The present invention-relates to a body suitable for use in the labelled quantitative determination of a biologically derived sample substance. Such determination can be by radioimmunoassay, fluorometry or spectrophotometry, for example.
As is defined herein, the term "sample substance" is-one which is contained in-a biological fluid.
Sample substances include antigens, antibodies, hormones, enzymes, drugsrinfectious agents and other substances. The sample substance is reacted with a diagnostic reagent covalently attached to a continuous solid surface. As defined herein, "diagnostic reagent" is one which is attached to a surface and specifically reacts directly or indirectly with the sample substance.
The diagnostic-reagent is further reacted with a labelled substance for quantitative measurement.
The term "labelled substance" is defined as a substance which includes a material detectible by a detection device and which is specifically reactive with the sample substance or diagnostic reagent. The sample substance itself sometimes may be autofluorogenic (e.g., tetracycline or enzymatic, e.g., trypsin) or can be made so in situ.
Labels include fluorochromes, radionuclides and -enzymes.
The labelled substances may be reacted with the sample substance before or after isolation, or may be linked to the solid surface with homologous labelled materials (e.g., antigen or antibody, one of which has been labelled).
For simplicity of description, the present specification will first describe a typical fluorometrically labelled system of the sandwich type. The procedure may be summarized as including the following steps:
(1) diagnostic reagent (e.g., antibody) is covalently attached to a surface region of a solid body; (2) the attached diagnostic reagent is reacted with a sample substance (e.g., antigen) and bound to the surface region;
(3) the surface region is washed to remove unbound sample and solvent;
(4) the surface region is reacted with labelled substance (e.g., fluorochrome-labelled antibody);
(5) the surface region is again washed; and
(6) the body is transported to a detection station to measure the amount of labelled substance.
Referring to step one, the diagnostic reagent, antibody, is covalently attached to a nonparticulate, nonswellable, impermeable, continuous surface region of the body. Such covalent attachment may be performed directly between the diagnostic reagent and a surface reactive with the same. Examples of such surfaces include polymers such as polymethylmethacrylate; polystyrene, polyamide (nylon) and polysaccharides. Diagnostic reagents having carboxylic acid and amino groups are reactive with such surfaces.
In an indirect coupling technique, groups reactive with the above groups serving as bridges between the polymer surfaces and the diagnostic reagent may either by present in the basic polymer or coupled thereto by known chemical reactions. Such coupling reagents include amino groups, hydroxyl groups, mercapto groups, amido groups, and carboxy groups. Suitable coupling techniques between the polymer and diagnostic reagent are set forth in Bennich et al U.S. Patent 3,720,760.
Other covalent linkages may be performed indirectly with ceramic substrates by use of intermediate coupling agents as set forth in
Weetall Patent 3,652,761. Although that patent describes the coupling to microreticular surfaces, the techniques are also applicable to the continuous impermeable nonparticulate surface of the present body.
The so-called direct sandwich technique is performed as follows. A coupling reagent is first attached to the substrate. In one specific coupling technique, a polymeric surface, e.g., an acrylic, may be reacted with a coupling agent or spacer arm in a carbodiimide catalyzed nucleophilic substitution type reaction. Thereafter, the diagnostic reagent, e.g., antibody, is similarly covalently attached to the coupling agent.
In the following step, the body surface with covalently attached antibody is contacted with a fluid suspected of containing sample substance, e.g., antigen, reactive with the antibody. If present, the antigen reacts and combines to the antibody on the surface during an incubation period. It is highly advantageous to agitate the reactive surface during incubation. This provides a significantiy faster reaction time. In addition, it has been found to increase the reproducibility of the experimental results. For this purpose, as set forth hereinafter, the body is provided with a handle which can be used to stir the reactive surface region either mechanically or manually.
In the next step, after incubation with the sample serum containing antigen, the surface is simply separated from the solution and the surface is washed with a suitable solvent such as aqueous phosphate buffer or distilled water.
In the following step, the surface is contacted with a labelled substance, antibody solution labelled with a fluorochrome. The solution is again incubated for a sufficient time to complete the reaction between the labelled antibody and antigen. As with the incubation of sample, it is advantageous to agitate the solution during this incubation to decrease the reaction time as well as improve the reproducibility of the detection.
In the next step, the solution containing unbound labelled antibody is separated from the solid surface containing bound labelled antibody.
Subsequently, the reacted solid surface is thoroughly washed to remove residual free and - nonspecificaily bound antibody which may remain on the solid surface. The efficiency of this washing step is extremely important in obtaining accurate results. This, the surface is thoroughly washed with a suitable rinsing solution such as aqueous phosphate buffer or distilled water.
This washing step establishes the importance of the initial covalent attachment of the diagnostic reagent with the solid surface in the first step. If, for example, such reagent were merely coated as by adsorption on the solid surface, a portion of it together with accompanying labelled substance can be washed away during this vigorous washing procedure.
After washing, the body containing the labelled substance is transported to a detection station to measure the amount of the same.
By way of background, one standard technique for binding sample substances to substrate is called by immunologists the "Sandwich
Technique". In the conventional case, an antibody to the specific disease whose presence is being determined, is coated to the surface. A typical case uses the test for "Australian Antigen" in the blood which is regarded as prima facie evidence of hepatitis infection. The anti Australian antigenantibody is coated in a film to the plastic substrate. The serum of the subject suspected of carrying the antigen is reacted with the antibody.
If the antigen is present, it binds immunologically to the antibody. After a rinse with water to remove all unbound material, more antibody with a fluorescent label is added. It binds to the antigen if it is present. Then a final rinse removes all unbound labelled antibody. Such a technique is described in U.S. Patent 3,826,618 with respect to RIA. In the present invention, the antibody is first covalently attached to the surface. In a fluorometric system, the fluorescence, if any, emitted from the surface is detected by a fluorometer.
In another type of direct technique, the diagnostic reagent, e.g., antibody, is first covalently attached to the substrate as set forth above. Thereafter, the sample containing antigen, previously labelled as with fluorogen is contacted with the surface for immunological reaction between the antigen and antibody. The surface is then read by a fluorometer. This system is illustrated in Example 1, supra.
In another example of a sandwich technique, the body is-covalently attached with antigen-a preparation of Treponema palladium, for instance, if it is desired to determine antibodies for syphilis is the subject. The serum of the subject is incubated with the body, then rinsed. Then labelled antihuman antibodies (harvested from goat or rabbit) are added, incubated and rinsed. If human antibody for treponemae was present in the serum then it adhered to the body by immunoreaction and, in turn, captured the labelled antibodies from the goat, for example,
hence, a quantitative reading of titre for syphilis can be obtained. This is a modification of the standard accepted FTA-ABS Test (fluorescent treponemal antibody-adsorption) whereby the body system of this invention enables accurate quantitation.
Any infectious disease producing antibodies would be amenable to assay by this technique and include such diseases of public health interest as: syphilis, gonorrhea, "strep" throat infection, dysentry, salmonella infection, typhoid, rabies, serum hepatitis, influenza types, etc. This invention can also be useful in quality control in the food and pharmaceutical industries.
Also, as another application employing the predescribed techniques, it is often of value not only to diagnose the presence of disease (antigens) but determine the body's protective immunity to disease (antibody titre) as a result of deliberate innoculation or vaccination. As an example, a physician innoculates a child with D.P.T. vaccine to provide immunity to diphtheria, pertussis or whooping cough, and tetanus. He then assumes that all -3 have "taken". A test of the serum for antibody for each would, in fact, determine if all 3 antigens were effective in creating sufficient immunizing antibodies. Present technology does not allow this simple screening procedure.
When the method of the present invention is
used in the so-called competitive technique, the
foregoing systems are modified generally as
follows. Instead of coupling diagnostic reagent
(antibody)-sample (antigen)-labelled substance
(antibody), the labelled substance and sample of
the same type (e.g., antigen) are added
simultaneously to compete with each other for
diagnostic reagent (e.g., antibody) covalently
attached to the solid surface. After this incubation
or contact time, the solid surface is washed with
the same advantages as the sandwich technique.
Illustrations of the system of this invention
where antigens or antibodies in the strict sense
are not involved but where protein-binding
procedures are still employed include such
combinations as thyronine-binding globulin (TBG)
and thyroxine (T4), intrinsic factor and vitamin B,2, and bovine lactoglobulin and folic acid, for
example.
In all cases, one of the pair (a first type of
protein) may be covalently attached to a solid
surface and may also bind with and remove from
blood serum the other member of the pair (a
second type of substance capable of binding to the protein of the first type), competing with fluorochrome-labelled molecules of its own type.
These examples and the generalized use are
strictly analogous to the antibody-serum antigen
labelled antigen systems described in several of the immunological reactions.
In the present specification, diagnostic reagent comprises one of the above pair and the biologically derived substance includes the other two. The reaction product of the pair of substances are "bound" to each other.
In another type of competitive technique, a known quantity of antigen is covalently attached to the surface and is contacted with specific labelled antibody simultaneously with a solution of the same type of antigen of unknown quantity.
An RIA technique employing the above technique with a noncovalently bound surface in which radioactively labelled antibody in solution is measured is described in a paper by J. S.
Woodhead, et al, entitled "The
Immunoradiometric Assay and Related
Techniques", Br. Med. Bull. 30:44 (1974). In the present system, the antigen is covalently attached to the surface, the labelled antibody on the surface is measured, and a fluorescent label is preferred.
Variations can include the use of a variety of fluorescent labels such as lissamine-rhodamine,B,
D.A.N.S. (1 -dimethylamino-naphthalene-5- sulfonic acid) orthophthaladehyde, and fluorescamine, which are frequently used in fluorescence microscopy. The first two possess an orange or red emission spectrum rather than the yellow green of fluorescein and the second two possess a blue or green emission spectrum. The only variation in the fluorometer would be the change in excitation and emission filters used, as well as the change in the fluorescent label on the antibodies in the reagent kit.
The present technique is also applicable to the use of enzyme labelled systems. One such system is described in an article by Pesce et al entitled "use of Enzyme-Linked Antibodies to Measure
Serum Anti-DNA Antibody in Systemic Lupus
Erthyematosus", Clin. Chem. 20/3, 353-359 (1974). The described system differs from the one described herein in that the diagnostic reagent,
DNA, is adsorbed to a test tube support.
Thereafter, serum containing DNA antibodies is reacted with the coated tube followed by reaction with an anti-human gamma globulin peroxidase enzyme conjugate with the coated tube. Then a colored reaction product is developed by action of peroxidase on the substrate which is colorimetrically measured by conventional techniques.
The following description will make particular reference to the body employed for use in the above techniques. It includes two important characteristics; a handle means and at least one nonparticulate, nonswellable, impermeable, continuous surface region capable of covalent attachment to a diagnostic reagent. The handle means may, in some cases, be the side of a test tube or a portion of a solid object. A particular preferred handle means is a handle specifically formed to facilitate mechanical or manual handling of the body as for stirring or the like.
Referring specifically to Figure 1, a body (the handle not being shown for the sake of simplicity) is illustrated in conjunction with a fluorometric system. The body 10, has been bound with a standard fluorescent labelled substance, 11, i.e., of the same fluorescent substance as is used to label the antibody containing surface 12 at the lower portion of cylinder 10 and has a known titre as measured on the detection device which is employed in the test tube or assay; in this instance, a fluorometer. Suitably a blank space 1 3 is left around the surface of the cylinder 10, separating the upper and lower layers 11 and 12, respectively. The lower layer 12 may contain streptococcal fluorescent-labelled antibody prepared in any of the foregoing methods.The lower layer is immersed in the body liquid to determine if any of the suspected antigen or antibody is present in the serum being tested.
A fiber optical cable 14 conducts ultra-violet light from a light source 1 6. The light then passes through a suitable gelatin filter 18 which ensures that only light of the excited wavelength reaches the body and strikes the body surface whereupon it excites fluorescence of the fluorochrome labelled substance. Two fiber optical cables 1 9 and 20 are provided with respective filters 1 9a and 20a. One such cable 19 conducts fluorescent light from the standard fluorescent coating to a photomultiplier tube 21, and the other such cable 20 conducts emitted fluorescence from the lower fluorescent layer 12 to the photomultiplier tube 21. A chopper wheel 22 operated by motor 23 revolves and alternates the flow of light from each coating 11 and 12 to tube 21.In this manner, a direct comparison is obtained between the standard and test portions.
In the embodiment of Figure 2, a paddle shaped body 26 includes a handle 27, a stem 23, and a wide, flat head 29 at the other end, the head 29 bearing in a layer 30 of sample. In this embodiment, a fluorometer is illustrated in which two fiber optic cables 31 (for excitation light) and 32 (for emitted fluorescent light) are parallel to each other.
In the embodiment of Figure 3, a multiple test body is illustrated. The body includes a cube 33 at the end of handle 34. The cube 33 can present four faces, two faces 36 and 37 being visible.
Each face has a different sample layer. This body is particularly adapted for fluorometry. Thus, four different fluorescent labels can be provided, and the fluorometer may have a filter wheel with four selected wavelength regions to isolate energy going to photomultiplier tube 21. As the operator rotates the tube 33 (or other multifaceted polyhedral body), each test can be read in sequence. A handle can similarly be attached to a cylinder, sphere or other substrate. Other means of moving the substrate upon which different biologically-derived substances are layered may be employed to vary the surface exposed to the fluorometer.
Broadly stated, the banded cylinder of Figure 1 and the cube of Figure 3 constitute two forms of the use of multiple areas coated on the substrate adapted for rapid multiple quantitative determination, especially of the fluorometric type.
Any shape of substrate may be employed so long as it includes a first area of sample substrate labelled as with a fluorochrome and at least one other area of such labelled substance. Such different areas may include a standard area of predetermined quantity of the same type of substance as the fluorochrome-labelled substance. In this manner, two different areas, such as bands 11 and 12 of Figure 1, may be viewed to provide a direct comparison of the standard and test portions.
In another embodiment, a single surface region may include a plurality of labelled substances in random dispersion chemically attached to the substrate. At least two of the labels for the sample are fluorochrome which emit fluorescence responsive to different wavelengths of light.
These may be employed in cases where it is desirable to detect the presence of more than one sample substance.
To detect the above randomly dispersed labelled substances of different wavelengths, a fluorometer may be equipped with a filter wheel so that several different wavelenths can be selected for several particular fluorescent labels, e.g., (1) fluorescein isothiocyanate, (yellowgreen); (2) lissamine rhodamine B-200 (deep orange); (3) D.A.H.5. (1-dimethylamino- naphthalene-5-sulfonic acid; red); (4) orthophthalaldehyde (blue-green); and (5) fluorescamine (blue-green) and when each label is attached to a different antibody for three microorganisms of interest in urinary tract infections (B. coli, Pseudomonas, and
Staphylococcus), then one, two or all three may be simultaneously determined and identified.
Fluorescent label substances include sodium fluorescein isothiocyanate or other suitable substances. This particular fluorochrome having an excitation at 460 nanometers and emission at 520 nanometers is advantageous.
The surface region of the body is characterized by certain physical and chemical properties. The primary chemical property, set forth above, is its ability to covalently attach with the particular diagnostic reagent. With respect to the physical properties, such surface is nonparticulate, nonswellable, impermeable and continuous.
The nonparticulate nature of the body surface region distinguished it from microbeads or the like. It should have a sufficient surface area to present a microscopic single surface to the detector to enable integration of the fluorescent light or radioactivity from large aggregates of labelled substances thereby reducing sampling errors from sample to sample. Suitably such area is at least 1 millimeter square. The use of such loose particles, often used in radiactive assays, produce an ill-defined and difficult to control surface for uniform excitation and precise viewing of fluorescence.
Another characteristic of the surface is that it is impermeable to liquid. This distinguishes from gel-like microreticular beads. With such beads are employed for this purpose as set forth in the background, it is extremely difficult to wash their interstitial spaces free of nonspecifically bound and entrapped label reagent. By the use of impermeable surfaces, the washing procedure is faster and more efficient.
Another characteristic of the surface region is that it be continuous. This feature is related to impermeability. By formation of a continuous nonporous surface, the aforementioned difficulties of washing are avoided. It should be understood that a surface treated with acid or other reagent to assist coupling is within the scope of the invention even though the surface may be roughened. Any porosity, permeability, or discontinuity of such a roughened surface is negligible in comparison to the microreticular particles of the prior art.
Another feature of the surface region is that it be nonswellable. This contrasts to the threedimensional gels such as Sephadex which are difficult to wash free of unbound reagents and to control dimensionally.
Various Examples will now be given to assist in illustratimg the present invention.
Example 1
This Example illustrates a fluorescent measurement of an antibody-antigen reaction in which an antigen in solution is fluorescently labelled and reacted with an antibody immobilized on a surface. In this so-called "direct" technique, the fluorescence of the surface is proportional to the antigen concentration in solution.
Acid soaked polyamide strips were coated with anti-Streptolysin 0 by immersing them for 30 minutes in a slowly stirred solution of Anti
Streptolysin 0 diluted 1.8 in saline solution while
1% of a coupling agent, glutaraldehyde was slowly added. After water washing and drying the covalently attached strips were exposed to various concentrations of Streptolysin O Toxin in distilled water. Two ml of each concentration were first reacted with 0.2 ml of fluorescamine solution (40 mg in 100 ml acetone) to affect labelling of the antigen. The strips were then added and stirred for 30 minutes, removed,
water rinsed, and allowed to dry. They were then placed in the instrument, excited at a wavelength of 375 mm and fluorescence measured at a wavelength of 475 mm. The following results were obtained.
Streptolysin O Toxin Fluorescent
Dilution Signal
1:5 280
1:10 155
1:20 105
1:40 45
1:1000 5
Blank 0 Example 2
This Example illustrates a fluorescent measurement of bacteria in which bacteria in suspension are bound to a surface and reacted with fluorescently labelled antibody, in a so-called "sandwich" technique. The fluorescence of the surface is proportional to the bacterial concentration of the sample.
A pure culture of Streptococcus betahemolyticus Type A was grown in trypsin broth, autoclaved, centrifuged, and washed with phosphate buffer saline (PBS). The cells were resuspended in PBS to concentrations of 107, 106 and 103 organisms per ml.
DEAE-cellulose strips were coated with
Streptococcus A Antiserum by immersing them for 1 5 minutes in a stirred solution of antiserum diluted 1:16 in phosphate buffer while 0.5 ml of 50% of coupling agent, glutaraldehyde, was slowly added. After washing, the covalently attached individual strips were incubated for 5 minutes in 5 ml of each of the concentrations mentioned above, followed by washing with PBS.
Next, the strips were incubated for 5 minutes in a solution of fluorescein isothiocyanate labelled
Streptococcus A antibody diluted 1:4 in phosphate buffer, rinsed with buffer and air dried.
The strips were then placed in the instrument and the following readings were obtained.
Streptococcal
Concentration Fluorescent
Organisms per ml. Signal 107 840
106 305
103 122
While in this Example, attachment was obtained by the cross-linking of antiserum proteins into a strongly adhering film, covalent attachment directly to cellulose derivatives such as amino-cellulose are similarly possible.
Example 3
This Example describes the fluorescent measurement of multiple surfaces that have been exposed to a common solution containing several substances for which measurement is desired.
Three squares of cellulose were each reacted with a different immunogiobulin antibody (goat anti-human IgA, lgG, and IgH) using glutaraldehyde coupling agent. The cellulose squares mounted on a plastic strip are placed in a sample of serum diluted in suitable buffer. After incubation for ten minutes, the strip is removed and the three coated squares rinsed with buffer.
They are then reacted with a solution containing equally active concentrations of fluorescein isothiocyanate labelled goat anti-human IgA, lgG and IgH diluted in suitable buffer and allowed to incubate another ten minutes. The strips are again washed and each area is separately read in the instrument. The relative concentrations of the various immunoglobulins are so determined
Example 4
This Example describes the fluorescent measurement of a common surface exposed to a solution containing several substances for which individual measurements are desired.
A circular disc of polymethylmethacrylic acid containing a random mixture of the same three different immunoglobulin antibodies as set forth above are exposed to a sample of serum diluted in suitable buffer. After incubation for ten minutes, the strip is removed and rinsed with buffer. It is then incubated in a solution containing a mixture of goat antibodies to these immunoglobulins, each antibody labelled with a different fluorochrome, i.e., fluorescamine labelled goat anti-lgA, fluorescein isothiocyanate labelled goat anti-lgG, and rhodamine labelled goat anti-lgH diluted in suitable buffer and incubated for twenty minutes. The strip is removed and washed with buffer. It is then read sequentially in the instrument exciting first at 390 nm and reading emission at 485 nm, than at 480 nm and 520 nm, respectively, and finally at 520 nm and 595 nm, respectively. The concentrations of IgA, IgC, and IgM are so determined.
Claims (28)
1. A body suitable for use in the detection of a biologically derived sample, said body comprising handle means connected to at least one nonparticulate, nonswellable, impermeable, continuous, substantially flat surface region and a diagnostic reagent bound to at least one biologically derived labelled sample, said diagnostic reagent being covalently attached to said surface region.
2. A body as claimed in claim 1 in which said labelled sample is a fluorochrome- or enzymelabelled sample.
3. A body as claimed in claim 1 or claim 2 in which said surface region defines an area of at least one square millimeter.
4. A body suitable for use in the fluorometric detection of a biologically derived sample, said body comprising handle means connected to at least one nonparticulate, nonswellable, impermeable, continuous, substantially flat surface region defining an area of at least one square millimeter and a diagnostic reagent bound to at least one biologically derivod sample labelled with a fluorochrome, said diagnostic reagent being covalently attached to said surface region.
5. A body as claimed in claim 4 together with at least one additional separate nonparticulate, nonswellable, impermeable, continuous, substantially flat surface region covalently attached to one other diagnostic reagent bound to at least one biologically derived sample labelled with a fluorochrome, said other diagnostic reagent being covalently attached to said additional surface region.
6. A body as claimed in claim 5 in which said additional region comprises a standard region including a predetermined quantity of a substance analytically identical with said fluorochromelabelled sample.
7. A body as claimed in claim 5 in which said surface region is polyhedral and has a different one of said labelled samples and/or said substances on each of a plurality of its faces.
8. A body as claimed in claim 4 in which said surface region includes a plurality of said labelled sample substances attached to said diagnostic reagent in random dispersion, at least two of the fluorochrome labels for said sample emitting fluorescence responsive to different wavelengths of light.
9. A body as claimed in claim 1 in which said handle means is one hereinbefore described in exemplification thereof.
10. A body as claimed in claim 1 in which the label of said labelled sample is one hereinbefore described in exemplification thereof.
11. A body as claimed in claim 1 in which said diagnostic reagent is one hereinbefore described in exemplification thereof.
12. A body as claimed in claim 1 in which said surface region is one hereinbefore described in exemplification thereof.
13. A body as claimed in claim 1 and substantially as hereinbefore described with reference to and as illustrated in any one of the figures of the accompanying drawings.
14. A body as claimed in claim 1 and substantially as hereinbefore described in any one of the Examples.
1 5. A body as claimed in any one of claims 1 to 14 in combination with a fluorometer, the receiving end of said fluorometer being adjacent to said surface region.
1 6. A method for the detection of an unknown
quantity of a biologically derived sample
substance comprising the steps of:
(a) covalently attaching a diagnostic reagent
capable of binding with said sample substance to
at least one nonparticulate, nonswellable,
impermeable, continuous, flat surface region of a
body connected to handle means;
(b) contacting the reagent bonded flat surface
of step (a) with said sample substance capable of
reacting with said diagnostic reagent in solution
and with a labelled substance in solution for a
sufficient time to form a labelled reaction product
capable of detection;
(c) separating the reacted surface and solution
containing unbound labelled substance after
completion of step (b);
(d) washing the reacted surface separated in
step (c); and
(e) quantitatively measuring the amount of
label of the washed reacted surface obtained in
step (d).
1 7. A method as claimed in claim 16 in which
said diagnostic reagent, said surface region, said
labelled substance, and/or said handle means
is/are one(s) hereinbefore described in exemplification thereof.
18. A method as claimed in claim 16 or claim 1 7 in which said quantitative measurement is effected substantially as hereinbefore described.
1 9. A method for the fluorometric detection of an unknown quantity of a biologically derived sample substance comprising the steps of:
(a) covalently attaching a diagnostic reagent capable of binding with said sample substance to at least one nonparticulte, nonswellable, impermeable continuous, flat surface region of a body;
(b) contacting the reagent-bonded flat surface of step (a) with said sample substance capable of reacting with said diagnostic reagent in solution and with a fluorochrome labelled substance in solution for a sufficient time to form a fluorochrome labelled reaction product capable of detection;
(c) separating the reacted surface and solution containing unbound fluorochrome labelled substance after completion of step (b);
(d) washing the reacted surface separated in step (c); and
(e) transporting the body to the detection station of a fluorometer and quantitatively measuring the amount of fluorescence emitted from the washed reacted surface obtained in step (d).
20. A method as claimed in claim 19 in which in step (b) said contacting with said sample substance is performed by gripping the body by a handle attached thereto, contacting said reagentbonded surface with a container of solution of said sample substance, and moving said surface relative to the body of said solution.
21. A method as claimed in claim 20 in which the body is dipped into said container of solution and said movement is performed by stirring with the handle.
22. A method as claimed in claim 20 in which the body is dipped into said container of solution and said movement is performed by agitating said container.
23. A method as claimed in any one of claims 19 to 22 in which in step (c) said sample substance is reacted with said diagnostic reagent and washed prior to reaction with said labelled substances, said latter substance being reactive with said sample substance.
24. A method as claimed in any one of claims 19 to 22 in which in step (c) said sample substance is simultaneously reacted with said diagnostic reagent and labelled substance, said latter substance being reactive with said diagnostic reagent.
25. A method for the fluorometric detection of an unknown quantity of a biologically derived sample substance comprising the steps of:
(a) covalently attaching a diagnostic reagent capable of binding with said sample substance to at least one nonparticulate, nonswellable, impermeable continuous, flat surface region of a body;
(b) contacting the reagent-bonded surface of
step (a) with a fluorescently labelled sample
substance reactive with said diagnostic reagent in
solution for a sufficient time to form a fluorescent
reaction product capable of fluorometric I detection; (c) separating the reacted surface and solution
containing unbound labelled sample substance
after completion of step (b);
(d) washing the reacted surface separated in
step (c); and
(e) transporting the body to the detection
station of a fluorometer and measuring the
amount of labelled substance on the washed
reacted surface obtained in step (d).
26. A method for the detection of an
unknown quantity of a biologically derived sample
substance which employs a body as claimed in
any one of claims 1 to 1 5.
27. A method as claimed in claim 16 or claim
19 substantially as hereinbefore described.
28. A method for the detection of an unknown
quantity of a biologically derived sample
substance substantially as hereinbefore described
in any one of the Examples.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB7842687A GB2034030A (en) | 1978-10-31 | 1978-10-31 | Analytical Test Article and Method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB7842687A GB2034030A (en) | 1978-10-31 | 1978-10-31 | Analytical Test Article and Method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB2034030A true GB2034030A (en) | 1980-05-29 |
Family
ID=10500716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB7842687A Withdrawn GB2034030A (en) | 1978-10-31 | 1978-10-31 | Analytical Test Article and Method |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2034030A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0070300A4 (en) * | 1981-01-23 | 1983-06-15 | American Hospital Supply Corp | Solid phase system for ligand assay. |
| EP0165072A3 (en) * | 1984-06-15 | 1986-12-30 | Mast Immunosystems, Inc. | Specific binding assay reagent medium, test kit and process |
-
1978
- 1978-10-31 GB GB7842687A patent/GB2034030A/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0070300A4 (en) * | 1981-01-23 | 1983-06-15 | American Hospital Supply Corp | Solid phase system for ligand assay. |
| EP0165072A3 (en) * | 1984-06-15 | 1986-12-30 | Mast Immunosystems, Inc. | Specific binding assay reagent medium, test kit and process |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4133639A (en) | Test article including a covalently attached diagnostic reagent and method | |
| KR920009420B1 (en) | Solid phase analysis device and method of using the same | |
| JP2514878B2 (en) | Solid phase assay device and method of using the same | |
| US5496700A (en) | Optical immunoassay for microbial analytes using non-specific dyes | |
| US5236826A (en) | Immunoassay for the detection or quantitation of an analyte | |
| US5501949A (en) | Particle bound binding component immunoassay | |
| WO2004003560A1 (en) | Enhanced diffraction-based biosensor devices | |
| EP0564494B1 (en) | Test method and reagent kit therefor | |
| WO1987003690A1 (en) | Particle-bound binding component immunoassay | |
| JPS6132621B2 (en) | ||
| EP0515370B1 (en) | A solid-phase interferometric immunoassay system | |
| US4540660A (en) | Substrate for fluoroimmunoassay of biological fluids | |
| EP0201211A1 (en) | Method and compositions for visual solid phase immunoassays based on luminescent microspheric particles | |
| JP3290660B2 (en) | Unit-of-use reagent composition for specific binding assay | |
| US4808524A (en) | Test kit and method for the determination of Streptococcus A antigen | |
| USRE33850E (en) | Test kit and method for the determination of Streptococcus A antigen | |
| EP1700128B1 (en) | Method for serological diagnosis and determination of immunisation status, comprising various controls | |
| EP0280557B1 (en) | Test kit, extraction device and method for the determination of streptococcus a antigen | |
| GB2034030A (en) | Analytical Test Article and Method | |
| CA1094931A (en) | Analytical test article and method | |
| CA2119125A1 (en) | Unit-of-use reagent compositions for specific binding assays | |
| EP1774336B1 (en) | Method for determining the immunisation status of a person | |
| JPH11258236A (en) | Antiphospholipid antibody measurement reagent | |
| CA1245981A (en) | Solid phase biological diagnostic assay | |
| EP0439211A1 (en) | Antibody composition for actinobacillus actinomycetemcomitans and its use in diagnostics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |